株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

糖尿病性末梢神経障害:パイプライン分析

Diabetic Peripheral Neuropathy - Pipeline Review, H2 2019

発行 Global Markets Direct 商品コード 257787
出版日 ページ情報 英文 78 Pages
即納可能
価格
本日の銀行送金レート: 1USD=110.59円で換算しております。
Back to Top
糖尿病性末梢神経障害:パイプライン分析 Diabetic Peripheral Neuropathy - Pipeline Review, H2 2019
出版日: 2019年11月29日 ページ情報: 英文 78 Pages
概要

糖尿病が原因で発症する神経障害のことを糖尿病性神経障害と言いますが、特に腕部・手・脚部・足で発生するものは糖尿病性末梢神経障害として知られています。主な症状として、足のしびれや刺すような痛み、脚部の不快感(鋭い痛みなど)、足・下腿部の筋力低下や筋緊張の弛緩、バランス感覚の喪失、足の肌の乾燥やひび割れなどがあります。主な疾病素質としては、糖尿病や喫煙、腎疾患などがあります。主な治療薬には、抗うつ剤や抗けいれん剤、オピオイド鎮痛薬などが含まれています。

当レポートでは、世界各国での糖尿病性末梢神経障害治療用のパイプライン製品の開発状況について分析し、パイプライン製品の開発・上市の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などを調査して、その結果を概略以下の構成でお届けします。

目次

イントロダクション

  • 分析範囲

糖尿病性末梢神経障害の概要

治療薬の開発

  • 糖尿病性末梢神経障害向けパイプライン製品:概要
  • 糖尿病性末梢神経障害向けパイプライン製品:比較分析

企業で開発中の治療薬

大学/機関で研究中の治療薬

パイプライン製品の概況

  • 後期段階の製品
  • 臨床段階の製品
  • 初期段階の製品

企業で開発中の製品

大学/機関で研究中の製品

治療薬開発に従事している企業

  • Acorda Therapeutics, Inc.
  • アステラス製薬
  • Cebix Incorporated
  • Pfizer Inc.
  • ViroMed Co., Ltd.

治療薬の評価

  • 単剤製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

  • Antimunocel
  • ASP-8477
  • BNV-222
  • capsaicin
  • CBX-129801
  • Drug for Pain
  • ketoprofen
  • NRD-135SE1
  • PF-05089771
  • Small Molecules for Peripheral Neuropathy and Amyotrophic Lateral Sclerosis
  • VM-202

最新パイプライン動向

休止中のプロジェクト

開発が中止された製品

製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

図表一覧

図表

List of Tables

  • Number of Products under Development for Diabetic Peripheral Neuropathy, H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019
  • Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019 (Contd..1), H2 2019
  • Number of Products by Stage and Target, H2 2019
  • Number of Products by Stage and Mechanism of Action, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
  • Diabetic Peripheral Neuropathy - Pipeline by Achelios Therapeutics Inc, H2 2019
  • Diabetic Peripheral Neuropathy - Pipeline by Applied Therapeutics Inc, H2 2019
  • Diabetic Peripheral Neuropathy - Pipeline by Bionevia Pharmaceuticals, H2 2019
  • Diabetic Peripheral Neuropathy - Pipeline by Calchan Ltd, H2 2019
  • Diabetic Peripheral Neuropathy - Pipeline by Celularity Inc, H2 2019
  • Diabetic Peripheral Neuropathy - Pipeline by Cleveland Diabetes Care Inc, H2 2019
  • Diabetic Peripheral Neuropathy - Pipeline by Commence Bio Inc, H2 2019
  • Diabetic Peripheral Neuropathy - Pipeline by CSPC Pharmaceutical Group Ltd, H2 2019
  • Diabetic Peripheral Neuropathy - Pipeline by Exodos Life Sciences Limited Partnership, H2 2019
  • Diabetic Peripheral Neuropathy - Pipeline by GNT Pharma Co Ltd, H2 2019
  • Diabetic Peripheral Neuropathy - Pipeline by Grunenthal GmbH, H2 2019
  • Diabetic Peripheral Neuropathy - Pipeline by Immune Pharmaceuticals Inc, H2 2019
  • Diabetic Peripheral Neuropathy - Pipeline by Jiangsu Aosaikang Pharmaceutical Co Ltd, H2 2019
  • Diabetic Peripheral Neuropathy - Pipeline by Medifron DBT Co Ltd, H2 2019
  • Diabetic Peripheral Neuropathy - Pipeline by Mitsubishi Tanabe Pharma Corp, H2 2019
  • Diabetic Peripheral Neuropathy - Pipeline by Praetego Inc, H2 2019
  • Diabetic Peripheral Neuropathy - Pipeline by Reata Pharmaceuticals Inc, H2 2019
  • Diabetic Peripheral Neuropathy - Pipeline by Seneca Biopharma Inc, H2 2019
  • Diabetic Peripheral Neuropathy - Pipeline by Sonnet BioTherapeutics Inc, H2 2019
  • Diabetic Peripheral Neuropathy - Pipeline by Sphaera Pharma Pte Ltd, H2 2019
  • Diabetic Peripheral Neuropathy - Pipeline by Winsantor Inc, H2 2019
  • Diabetic Peripheral Neuropathy - Pipeline by YD Life Science Co, H2 2019
  • Diabetic Peripheral Neuropathy - Pipeline by Zhejiang Pharmaceutical Co Ltd, H2 2019
  • Diabetic Peripheral Neuropathy - Dormant Projects, H2 2019
  • Diabetic Peripheral Neuropathy - Discontinued Products, H2 2019

List of Figures

  • Number of Products under Development for Diabetic Peripheral Neuropathy, H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Number of Products by Top 10 Targets, H2 2019
  • Number of Products by Stage and Top 10 Targets, H2 2019
  • Number of Products by Top 10 Mechanism of Actions, H2 2019
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
  • Number of Products by Routes of Administration, H2 2019
  • Number of Products by Stage and Routes of Administration, H2 2019
  • Number of Products by Molecule Types, H2 2019
  • Number of Products by Stage and Top 10 Molecule Types, H2 2019
目次
Product Code: GMDHC11857IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Diabetic Peripheral Neuropathy - Pipeline Review, H2 2019, provides an overview of the Diabetic Peripheral Neuropathy (Metabolic Disorders) pipeline landscape.

"Diabetic neuropathy is nerve damage caused by diabetes. The type of neuropathy occurring in the arms, hands, legsand feet is known as diabetic peripheral neuropathy. Symptoms include numbness or tingling in the feet pain ordiscomfort in the feet or legs-including prickly, sharp pain or burning feet, muscle weakness and loss of muscle tonein the feet and lower legs, loss of balance, dry feet and cracked skin. The predisposing factors include diabetes,smoking and kidney diseases. Treatment includes antidepressants, anti-seizure and opioid analgesics."

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Diabetic Peripheral Neuropathy - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Diabetic Peripheral Neuropathy (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Diabetic Peripheral Neuropathy (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Diabetic Peripheral Neuropathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 1, 8, 4, 1 and 9 respectively.

Diabetic Peripheral Neuropathy (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Diabetic Peripheral Neuropathy (Metabolic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Diabetic Peripheral Neuropathy (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Diabetic Peripheral Neuropathy (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Diabetic Peripheral Neuropathy (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Diabetic Peripheral Neuropathy (Metabolic Disorders)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Diabetic Peripheral Neuropathy (Metabolic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Diabetic Peripheral Neuropathy (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Diabetic Peripheral Neuropathy - Overview
  • Diabetic Peripheral Neuropathy - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Products under Development by Companies
  • Diabetic Peripheral Neuropathy - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Diabetic Peripheral Neuropathy - Companies Involved in Therapeutics Development
  • Achelios Therapeutics Inc
  • Applied Therapeutics Inc
  • Bionevia Pharmaceuticals
  • Calchan Ltd
  • Celularity Inc
  • Cleveland Diabetes Care Inc
  • Commence Bio Inc
  • CSPC Pharmaceutical Group Ltd
  • Exodos Life Sciences Limited Partnership
  • GNT Pharma Co Ltd
  • Grunenthal GmbH
  • Immune Pharmaceuticals Inc
  • Jiangsu Aosaikang Pharmaceutical Co Ltd
  • Medifron DBT Co Ltd
  • Mitsubishi Tanabe Pharma Corp
  • Praetego Inc
  • Reata Pharmaceuticals Inc
  • Seneca Biopharma Inc
  • Sonnet BioTherapeutics Inc
  • Sphaera Pharma Pte Ltd
  • Winsantor Inc
  • YD Life Science Co
  • Zhejiang Pharmaceutical Co Ltd
  • Diabetic Peripheral Neuropathy - Drug Profiles
  • (amitriptyline + ketamine hydrochloride) - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • (diclofenac sodium + triclocarban) - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • AAD-2004 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • AT-001 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • atexakin alfa - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • BNV-222 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • CNV-2197944 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • dextrose lipoic acid tromethamine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • elismetrep - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ketoprofen - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • KU-32 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • MDR-16523 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • MDR-652 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • MSC-2 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • NSI-189 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • PDA-002 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • pirenzepine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • PTG-605 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules for Pain - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • sodium nitrite SR - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • SYHA-1402 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • YD-308 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • YJ-001 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Diabetic Peripheral Neuropathy - Dormant Projects
  • Diabetic Peripheral Neuropathy - Discontinued Products
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer
Back to Top